Cargando…
Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia
Chimeric antigen receptor (CAR) T-cell therapies that specifically target the CD19 antigen have emerged as a highly effective treatment option in patients with refractory B-cell hematological malignancies. Safety and efficacy outcomes from the pivotal prospective clinical trials of axicabtagene cilo...
Autores principales: | Myers, G Doug, Verneris, Michael R, Goy, Andre, Maziarz, Richard T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047987/ https://www.ncbi.nlm.nih.gov/pubmed/33846220 http://dx.doi.org/10.1136/jitc-2020-002056 |
Ejemplares similares
-
Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells
por: Feng, Jia, et al.
Publicado: (2021) -
Treatment of aggressive T-cell lymphoma/leukemia with anti-CD4 CAR T cells
por: Feng, Jia, et al.
Publicado: (2022) -
CAR T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia
por: Saleh, Khalil, et al.
Publicado: (2023) -
Identification of methylation signatures associated with CAR T cell in B-cell acute lymphoblastic leukemia and non-hodgkin’s lymphoma
por: Song, Jiwei, et al.
Publicado: (2022) -
CAR T-Cells in Acute Lymphoblastic Leukemia: Current Status and Future Prospects
por: Almaeen, Abdulrahman H., et al.
Publicado: (2023)